<DOC>
	<DOC>NCT00994266</DOC>
	<brief_summary>The purpose of this study is to assess the efficacy of Diamel (dietary supplement) administration in the treatment of patients with type 2 diabetes receiving insulin therapy. The duration of this double-blind placebo controlled phase 3 clinical trial will be 24 weeks. The estimated number of patients to be recruited and randomized for the study is 116. Daily insulin requirements, blood glucose (fasting and post-prandial) concentrations, glycosylated hemoglobin (HbA1c), triglycerides and cholesterol will be assessed at the beginning and after 24 weeks of treatment.</brief_summary>
	<brief_title>Diamel in the Treatment of Type 2 Diabetic Patients Receiving Insulin Therapy</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Type 2 diabetes with insulin therapy regimen of two daily doses. Signed informed consent. Type 1 diabetes. Type 2 diabetes with glibenclamide treatment. Nephropathy or liver condition diagnosed by clinical and/or biochemical examination. Sepsis. Pregnancy. HbA1c values greater than 10%.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Type 2 diabetes</keyword>
	<keyword>Diamel</keyword>
	<keyword>Dietary supplement</keyword>
</DOC>